Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, People's Republic of China; Department of Obstetrics and Gynecology, The affiliated Hospital of Southwest Medical University, Luzhou 646000, People's Republic of China.
Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, People's Republic of China.
Gynecol Oncol. 2019 Feb;152(2):259-264. doi: 10.1016/j.ygyno.2018.11.034. Epub 2018 Dec 14.
The study aimed to investigate the prognostic value of the systemic immune-inflammation index (SII) in patients with epithelial ovarian cancer (EOC).
A total of 553 EOC patients were retrospectively analyzed. 250 patients from West China Second University Hospital were assigned into the discovery cohort and 283 patients from The Affiliated Hospital of Southwest Medical University were assigned into the validation cohort. The correlation between SII and survival were analyzed using Cox regression analyses and Kaplan-Meier method. Prediction accuracy was evaluated with the receiver operating characteristics (ROC) curve.
The high SII (≥612) was correlated with advanced FIGO stage, lymph node metastasis, and tumor recurrence. In univariate Cox regression, patients with high SII (≥612) had a significantly shorter progression-free survival (PFS) and overall survival (OS) compared to low SII patients (<612) in both cohorts. In multivariate Cox regression analysis, SII was an independent prognostic indicator for PFS (HR = 7.61, 95% CI 3.34-17.35, P < 0.001) and OS (HR = 6.36, 95% CI 2.64-15.33, P < 0.001) in the discovery cohort. These results were verified in the validation cohort.
High SII was correlated with poor survival in patients with EOC. The SII was an independent prognostic factor for patients with EOC.
本研究旨在探讨全身免疫炎症指数（SII）在卵巢上皮癌（EOC）患者中的预后价值。
回顾性分析了 553 例 EOC 患者。其中，250 例来自四川大学华西第二医院的患者被纳入发现队列，283 例来自西南医科大学附属医院的患者被纳入验证队列。采用 Cox 回归分析和 Kaplan-Meier 法分析 SII 与生存的相关性。采用受试者工作特征（ROC）曲线评估预测准确性。
高 SII（≥612）与 FIGO 分期较晚、淋巴结转移和肿瘤复发有关。在单因素 Cox 回归中，发现队列中高 SII（≥612）患者的无进展生存期（PFS）和总生存期（OS）明显短于低 SII 患者（<612）。多因素 Cox 回归分析显示，SII 是 PFS（HR=7.61，95%CI 3.34-17.35，P<0.001）和 OS（HR=6.36，95%CI 2.64-15.33，P<0.001）的独立预后指标。这些结果在验证队列中得到了验证。
高 SII 与 EOC 患者的不良生存相关。SII 是 EOC 患者的独立预后因素。
